4.6 Article

Replication-Defective West Nile Virus with NS1 Deletion as a New Vaccine Platform for Flavivirus

Journal

JOURNAL OF VIROLOGY
Volume 93, Issue 17, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.00720-19

Keywords

flavivirus; NS1; West Nile virus; vaccine

Categories

Funding

  1. National Key Research and Development Program of China [2016YFD0500400]
  2. National Natural Science Foundation of China [81572003]

Ask authors/readers for more resources

We previously produced a replication-defective West Nile virus (WNV) lacking NS1 (WNV-Delta NS1) that could propagate at low levels (105 infectious units [IU]/ml) in a 293T cell line expressing wild-type (WT) NS1. This finding indicates the potential of developing WNV-Delta NS1 as a noninfectious vaccine. To explore this idea, we developed an NS1-expressing Vero cell line (Vero(NS1)) that significantly improved the yield of WNV-Delta NS1 (10(8) IU/ml). We evaluated the safety and efficacy of WNV-Delta NS1 in mice. WNV-Delta NS1 appeared to be safe, as no replicative virus was found in naive Vero cells after continuous culturing of WNV-Delta NS1 in Vero(NS1) cells for 15 rounds. WNV-Delta NS1 was noninfectious in mice, even when IFNAR(-/-) mice were administered a high dose of WNV-Delta NS1. Vaccination with a single dose of WNV-Delta NS1 protected mice from a highly lethal challenge with WT WNV. The antibody response against WNV correlated well with the protection of vaccinated mice. Our study demonstrates the potential of the NS1 trans complementation system as a new platform for flavivirus vaccine development. IMPORTANCE Many flaviviruses are significant human pathogens that frequently cause outbreaks and epidemics around the world. Development of novel vaccine platforms against these pathogens is a public health priority. Using WNV as a model, we developed a new vaccine platform for flaviviruses. WNV containing a NS1 deletion (WNV-Delta NS1) could be efficiently trans complemented in Vero cells that constitutively expressed WT NS1 protein. A single-dose immunization with WNV-Delta NS1 elicited robust immune responses in mice. The immunized animals were fully protected against pathogenic WNV infection. No adverse effects related to the WNV-Delta NS1 vaccination were observed. The results have demonstrated the potential of the NS1 complementation system as an alternative platform for flavivirus vaccine development, especially for highly pathogenic flaviviruses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice

Na Li, Zhe-Rui Zhang, Ya-Nan Zhang, Jing Liu, Cheng-Lin Deng, Pei-Yong Shi, Zhi-Ming Yuan, Han-Qing Ye, Bo Zhang

NPJ VACCINES (2020)

Article Biochemistry & Molecular Biology

Crystal structure of a tick-borne flavivirus RNA-dependent RNA polymerase suggests a host adaptation hotspot in RNA viruses

Jieyu Yang, Xuping Jing, Wenfu Yi, Xiao-Dan Li, Chen Yao, Bo Zhang, Zhenhua Zheng, Hanzhong Wang, Peng Gong

Summary: Research on RNA-dependent RNA polymerases (RdRPs) in RNA viruses found that a region between RdRP catalytic motifs B and C showed host-related diversity. Substitutions in this region did not significantly affect RdRP catalytic activities but did not support virus proliferation.

NUCLEIC ACIDS RESEARCH (2021)

Article Microbiology

RNA Interference Screening Reveals Requirement for Platelet-Derived Growth Factor Receptor Beta in Japanese Encephalitis Virus Infection

Minmin Zhou, Shaobo Wang, Jiao Guo, Yang Liu, Junyuan Cao, Xiaohao Lan, Xiaoying Jia, Bo Zhang, Gengfu Xiao, Wei Wang

Summary: PDGFR beta was identified as a potential therapeutic target against JEV infection, with the inhibitor imatinib showing protection against JEV-induced lethality by reducing viral load in the brain and preventing histopathological changes.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Article Biotechnology & Applied Microbiology

SARS-CoV-2 replicon for high-throughput antiviral screening

Qiu-Yan Zhang, Cheng-Lin Deng, Jing Liu, Jia-Qi Li, Hong-Qing Zhang, Na Li, Ya-Nan Zhang, Xiao-Dan Li, Bo Zhang, Yi Xu, Han-Qing Ye

Summary: An SARS-CoV-2 replicon was constructed for safe antiviral screening in BSL-2 laboratories, providing an effective platform for evaluating inhibitors and establishing a high-throughput screening assay. The replicon-based assay was validated using hit natural compounds from a previous cytopathic-effect-based HTS assay, demonstrating its potential for antiviral research without using live virus.

JOURNAL OF GENERAL VIROLOGY (2021)

Article Virology

In Vitro Inhibition of Alphaviruses by Lycorine

Na Li, Zhen Wang, Rui Wang, Zhe-Rui Zhang, Ya-Nan Zhang, Cheng-Lin Deng, Bo Zhang, Lu-Qing Shang, Han-Qing Ye

Summary: Lycorine can inhibit CHIKV in cell culture without cytotoxicity and exhibits broad-spectrum anti-alphavirus activity at an early post-entry stage of CHIKV life cycle.

VIROLOGICA SINICA (2021)

Article Virology

High-Titer Self-Propagating Capsidless Chikungunya Virus Generated in Vero Cells as a Strategy for Alphavirus Vaccine Development

Ya-Nan Zhang, Zhe-Rui Zhang, Na Li, Xin-Ru Pei, Xiao-Dan Li, Cheng-Lin Deng, Han-Qing Ye, Bo Zhang

Summary: This study successfully propagated Chikungunya virus in Vero cells through the construction of a chimeric VEEV-Delta C-CHIKV, significantly improving its yield. The passaged VEEV-Delta C-CHIKV demonstrated the safety and practicality of utilizing infectious capsidless viral particles of Chikungunya virus as a vaccine candidate.

JOURNAL OF VIROLOGY (2022)

Article Immunology

A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon

Na Li, Xiao-Ling Chen, Qi Li, Zhe-Rui Zhang, Cheng-Lin Deng, Bo Zhang, Xiao-Dan Li, Han-Qing Ye

Summary: This study establishes a more convenient and efficient method for rapid screening of inhibitors blocking syncytium formation using VEEV-SARS-CoV-2-S-eGFP replicating cells. The assay can be performed in a BSL-2 laboratory without manipulation of live SARS-CoV-2.

EMERGING MICROBES & INFECTIONS (2022)

Article Pharmacology & Pharmacy

A safe replication-defective Zika virus vaccine protects mice from viral infection and vertical transmission

Na Li, Cheng-Lin Deng, Qi Li, Xiao-Ling Chen, Bo Zhang, Han-Qing Ye

Summary: High titers of replication-defective ZIKV with NS1 deletion (ZIKV-Delta NS1) were generated using the NS1 transcomplementation system. ZIKV-Delta NS1 vaccine induced antibody responses and provided protection against ZIKV infection in mice. Moreover, ZIKV-Delta NS1 vaccination attenuated vertical transmission during pregnancy. These findings highlight the potential of the NS1 trans-complementation system for developing flavivirus vaccines.

ANTIVIRAL RESEARCH (2023)

Correction Virology

Different Degrees of 5′-to-3′ DAR Interactions Modulate Zika Virus Genome Cyclization and Host-Specific Replication (vol 94, e01602, 2020)

Xiao-Dan Li, Cheng-Lin Deng, Zhi-Ming Yuan, Han-Qing Ye, Bo Zhang

JOURNAL OF VIROLOGY (2023)

Article Virology

A high throughput antiviral screening platform for alphaviruses based on Semliki Forest virus expressing eGFP reporter gene

Yu-Jia Shi, Jia-Qi Li, Hong-Qing Zhang, Cheng-Lin Deng, Qin-Xuan Zhu, Bo Zhang, Xiao-Dan Li

Summary: This article describes the establishment of a high throughput screening (HTS) platform based on a recombinant Semliki Forest virus (SFV) for studying antiviral drugs against mosquito-borne alphaviruses. By using the SFV-eGFP reporter virus, a 96-well format HTS assay was successfully established and optimized, allowing rapid screening of broad-spectrum alphavirus inhibitors.

VIROLOGICA SINICA (2023)

Letter Biochemistry & Molecular Biology

An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques

Yuanyuan Li, Yanan Zhang, Yu Zhou, Yan Li, Jiao Xu, Yuanbao Ai, Lei Xu, Xiuli Xiao, Bo Zhang, Jing Jin

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Letter Biochemistry & Molecular Biology

An alphavirus replicon particle delivering prefusion-stabilized spike protein provides potent immunoprotection against SARS-CoV-2 Omicron variant

Hong-Qing Zhang, Ya-Nan Zhang, Zhe-Rui Zhang, Xiao-Ling Chen, Yan-Yan Hu, Yu-Jia Shi, Jing Wang, Cheng-lin Deng, Bo Zhang, Xiao-Dan Li, Han-Qing Ye

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Letter Biochemistry & Molecular Biology

ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants

Jianxia Ou, Yanan Zhang, Yongmei Wang, Zherui Zhang, Hongping Wei, Junping Yu, Qi Wang, Guifeng Wang, Bo Zhang, Chunhe Wang

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Article Biochemistry & Molecular Biology

Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice

Jia-Qi Li, Zhe-Rui Zhang, Hong-Qing Zhang, Ya-Nan Zhang, Xiang-Yue Zeng, Qiu-Yan Zhang, Cheng-Lin Deng, Xiao-Dan Li, Bo Zhang, Han-Qing Ye

Summary: The study demonstrated a safe and cost-effective method to prevent SARS-CoV-2 infection by expressing neutralizing antibodies in the lungs. Through in vitro and in vivo assays, it was shown that self-replicating mRNA could efficiently block SARS-CoV-2 infection with reduced viral titer and tissue damage in the lung with the help of lung target delivery using the VRP system.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Letter Biochemistry & Molecular Biology

Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner

Shichao Huang, Yu'e Liu, Yanan Zhang, Ru Zhang, ChengJie Zhu, Lihong Fan, Gang Pei, Bo Zhang, Yufeng Shi

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

No Data Available